David P. Southwell Sells 10,000 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director David P. Southwell sold 10,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $24.05, for a total value of $240,500.00. Following the transaction, the director now directly owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ:RCKT opened at $23.48 on Friday. The business’s fifty day moving average price is $27.33 and its two-hundred day moving average price is $25.26. The stock has a market cap of $2.12 billion, a PE ratio of -7.99 and a beta of 1.07. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.80 and a current ratio of 7.80. Rocket Pharmaceuticals, Inc. has a one year low of $14.89 and a one year high of $32.53.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.14. During the same period last year, the firm posted ($0.92) EPS. On average, analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in shares of Rocket Pharmaceuticals by 2.2% during the fourth quarter. Wellington Management Group LLP now owns 8,197,546 shares of the biotechnology company’s stock worth $245,680,000 after purchasing an additional 174,716 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Rocket Pharmaceuticals by 18.3% during the fourth quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company’s stock worth $163,264,000 after acquiring an additional 843,552 shares during the last quarter. BlackRock Inc. increased its position in shares of Rocket Pharmaceuticals by 12.2% during the third quarter. BlackRock Inc. now owns 4,494,274 shares of the biotechnology company’s stock worth $71,727,000 after acquiring an additional 488,509 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Rocket Pharmaceuticals by 14.7% during the third quarter. Westfield Capital Management Co. LP now owns 4,193,996 shares of the biotechnology company’s stock worth $85,935,000 after acquiring an additional 538,209 shares during the last quarter. Finally, State Street Corp increased its position in shares of Rocket Pharmaceuticals by 1.0% during the first quarter. State Street Corp now owns 4,019,686 shares of the biotechnology company’s stock worth $68,857,000 after acquiring an additional 40,701 shares during the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. UBS Group lowered their price objective on Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, March 1st. StockNews.com raised Rocket Pharmaceuticals to a “sell” rating in a research report on Friday, February 9th. JPMorgan Chase & Co. lowered their price objective on Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, February 27th. The Goldman Sachs Group assumed coverage on Rocket Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “neutral” rating and a $39.00 price objective for the company. Finally, Lifesci Capital reaffirmed an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $52.13.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.